全文1820字,阅读约需6分钟,帮我划重点划重点01丽珠集团与一品红控股子公司丽珠单抗与华南疫苗达成最新BD交易,涉及四价流感重组蛋白疫苗项目,总金额达2.1亿元。02该四价流感重组蛋白疫苗项目目前处于临床申请阶段,计划于2024年8月8日获得国家药品监督管理局受理。03一品红在交易中有权获得该款疫苗的销售额提成,总额不超过20亿元人民币,详细财务条款已列出。04由于四价重组流感疫苗尚处于临床前期...
Source Link全文1820字,阅读约需6分钟,帮我划重点划重点01丽珠集团与一品红控股子公司丽珠单抗与华南疫苗达成最新BD交易,涉及四价流感重组蛋白疫苗项目,总金额达2.1亿元。02该四价流感重组蛋白疫苗项目目前处于临床申请阶段,计划于2024年8月8日获得国家药品监督管理局受理。03一品红在交易中有权获得该款疫苗的销售额提成,总额不超过20亿元人民币,详细财务条款已列出。04由于四价重组流感疫苗尚处于临床前期...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.